The impact of biologic response modifiers on hepatitis B virus infection

Expert Opinion on Biological Therapy

Volumn 11, Issue 4, 2011, Pages 533-544

  Carroll, Matthew B ^a  

^a KEESLER MEDICAL CENTER   (United States)

Author keywords

ankylosis spondylitis; B cells; cytokines; hepatitis B virus; rheumatoid arthritis; tumor necrosis factor

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD20 ANTIGEN; CD86 ANTIGEN; ENTECAVIR; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR; LAMIVUDINE; RITUXIMAB; TENOFOVIR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; CYTOKINE RESPONSE; DRUG RESPONSE; GENETIC POLYMORPHISM; HEPATITIS B; HUMAN; INFECTION CONTROL; INFECTION RISK; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 79952614900     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.554810     Document Type: Review

References (77)

1. Lok ASF. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
3. Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol 2009;15:3099-105
4. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
5. Ribeiro CSS, Visentainer JEL, Moliterno RA. Association of cytokine genetic polymorphisms with hepatitis B infection evolution in adult patients. Mem Inst Oswaldo Cruz 2007;102:435-40 (Pubitemid 46983741)
6. Hosel M, Quasdorff M, Wiegmann K, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-82
7. Larrubia JR, Benito-Martinez S, Miquel-Plaza J, et al. Cytokines-their pathogenic and therapeutic role in chronic viral hepatitis. Rev Esp Enferm Dig 2009;101:343-51
8. Ganem D, Prince AF. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29 (Pubitemid 38298992)
9. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16 (Pubitemid 32224400)
10. Rasheed Z, Haqqi TM. Update on targets of biologic therapies for rheumatoid arthritis. Curr Rheumatol Rev 2008;4:246-60
11. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Int Care Med 2004;19:320-34 (Pubitemid 44544695)
12. Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis. Drugs 2009;69:2035-43
13. Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf2004;3:391-403 (Pubitemid 39242714)
14. Furst DE. The risk ofinfections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46
15. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
16. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
17. Sibilia J, Westhovens R. Safety ofT-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(Suppl 46):S46-56 (Pubitemid 350167905)
18. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: A literature review and potential mechanisms of action. Clin Rheumatol 2010;29:1021-9
19. Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 2003;9:99-114 (Pubitemid 36531883)
20. Case JP. Old and new drugs used in rheumatoid arthritis: part 2. Am J Therapeutics 2001;8:163-79
21. Penn H. Biologic therapies in autoimmune diseases. Clin Med 2006;6:105-8
22. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-8 (Pubitemid 24065641)
23. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7 (Pubitemid 44542073)
24. Hohler T, Kruger A, Gerken G, et al. A tumour necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998;111:579-82 (Pubitemid 28160904)
25. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9 (Pubitemid 27157287)
26. Ben-Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-50 (Pubitemid 36135183)
27. Li HQ, Li Z, Liu Y, et al. Association of-238G/A and-857C/T polymorphisms of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection. Biomed Environ Sci 2006;19:133-6 (Pubitemid 43901642)
28. Li HQ, Li Z, Liu Y, et al. Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterol 2005;11:5213-17 (Pubitemid 41410342)
29. Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003;12:2541-6 (Pubitemid 37220418)
30. Cheong JY, Cho SW, Hwang IL, et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastro Hepatology 2006;21:1163-9
31. Niro GA, Fontana R, Gioffreda D, et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 2005;25:1175-81 (Pubitemid 41782562)
32. Du T, Guo XH, Zhu XL, et al. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J Viral Hepat 2006;13:618-24 (Pubitemid 44232546)
33. Fang JWS, Shen WW, Meager A, et al. Activations of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 1996;91:748-53 (Pubitemid 26117956)
34. Rehermann B. Intrahepatic T-cells in hepatitis B: viral control versus liver cell injury. J Exp Med 2000;191:1263-8 (Pubitemid 30227115)
35. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997;94:8744-9 (Pubitemid 27335110)
36. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred pre-emptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9 (Pubitemid 37500439)
37. Calabrese LH, Zein NN, Vassilopoulos D. Hepatits B virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9 (Pubitemid 44133258)
38. Saag K, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84 (Pubitemid 351847559)
39. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010;22:443-50
40. Raftery G, Griffiths B, Kay L, et al. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology 2007;46:1381 (Pubitemid 47244524)
41. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg negative and anti-HBs-positive patient. Liver Int 2008;28:718-20
42. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation [letter]. Inflamm Bowel Dis 2007;13:508-9 (Pubitemid 46668261)
43. Kim YJ, Bae SC, Sung YK, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010;37:346-50
44. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54
45. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:179-84
46. Zhang P-A, Li Y, Xu P, et al. Polymorphisms of interleukin-1B and interleukin-1 receptor antagonist genes in patients with chronic hepatitis B. World J Gastroenterol 2004;10:1826-9 (Pubitemid 38931215)
47. Ranjbar M, Alizadeh AHM, Hajilooi M, et al. Polymorphisms ofinterleukin-1R receptor antagonist genes in patients with chronic hepatitis B in Iran. World J Gastroenterol 2006;12:5044-7 (Pubitemid 44323276)
48. den Broeder AA, de Jong E, Franssen MJAM, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2 (Pubitemid 43799175)
49. Kineret. Washington DC: Drugs@FDA. 2004. Available from: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails [Last accessed 13 January 2011]
50. Carroll, Matthew B (matthew. carroll.1@us.afmil). 'Anakinra and HBV.' Email to Pilstrom Bjorn of Biovitrium (bjorn.pilstrom@sobi.com) 5 Aug 2010
51. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314 (Pubitemid 28448572)
52. Hushaw LL, Sawaqed R, Sweis G, et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010;6:143-52
53. Ataseven H, Bahcecioglu IH, Kuzu N, et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006;2006(4):78380
54. Liu Q, Feng GX, Lin YL, et al. Detection ofinterleukin-6 and-12in of hepatitis B patients and its clinical significance. Di Yi Jun Yi Da Xue Xue Bao 2001;21:858-9
55. Kuo TM, Hu C, Chen YL, et al. HBV replication is significantly reduced by IL-6. J Biomed Sci 2009;16:41-9
56. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-70
57. Li C, Zhi-Xin C, Li-Juan Z, et al. The association between cytokine gene polymorphisms and the outcomes of chronic HBV infection. Hepatol Res 2006;36:158-66 (Pubitemid 44575931)
58. Park BL, Lee HS, Kim YJ, et al. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003;35:76-82 (Pubitemid 36626937)
59. Fabris C, Toniutto P, Bitetto D, et al. Gene polymorphism at the interleukin 6-174 G>C locus affects the outcome of chronic hepatitis B. J Infection 2009;59:144-5
60. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47:1838-40
61. Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011: published onlone 8 October 2010. doi: 10.1007/s10165-010-0365-8
62. Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009;19:351-7
63. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B-cells. Seminars in Hematology 2010;47:170-9
64. Lazdina U, Cao T, Steinbergs J, et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B-cells. J Virol 2001;75:6367-74 (Pubitemid 32578155)
65. Tsutsumi Y, Yamamoto Y, Tanaka J, et al. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 2009;1:1053-61
66. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010;149:3-13
67. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608 (Pubitemid 40723731)
68. Pyrpasopoulou A, Douma S, Vassiliadis T, Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2009: published on line 13 September 2009, doi: 10.1007/s00296-009-1202-2
69. Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology 2008;47:1732-3
70. Sharpe AH, Abbas AK. T-Cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006;355:973-5 (Pubitemid 44343539)
71. Thio CL, Mosbruger TL, Kaslow RA, et al. Cytotoxic T-lymphocyte antigen 4 gene and recover from hepatitis B virus infection. J Virol 2004;78:11258-62 (Pubitemid 39299664)
72. Alizadeh AHM, Hajilooi M, Ranjbar M, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 2006;12:630-5 (Pubitemid 43380797)
73. Gu X, Qi P, Zhou F, et al. +49G>A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71:83-7
74. Levine, Loree. "Information you requested from Bristol-Myer-Squibb. " Message to Matthew B. Carroll. 12 August 2010. E-mail.
75. Pham T, Claudepierre P, Constantin A, et al. Abatacept therapy and safety management. Joint Bone Spine 2009;76(Suppl 1):S1-56
76. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71 (Pubitemid 44154702)
77. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39 (Pubitemid 46374607)